08:22 AM EDT, 09/24/2025 (MT Newswires) -- Soleno Therapeutics ( SLNO ) shares were up over 14% in recent Wednesday premarket activity after a rival therapy failed to meet its primary endpoint in a phase 3 trial.

Acadia Pharmaceuticals ( ACAD ) said its investigational therapy ACP-101 for patients with hyperphagia in Prader-Willi syndrome did not meet its primary efficacy endpoint in a phase 3 trial. Shares of the company were down nearly 12%.

Soleno previously said its treatment for hyperphagia in adults and children with Prader-Willi Syndrome has been approved by the US Food and Drug Administration and also received marketing authorization from the European Medicines Agency.